News from arena pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 30, 2015, 08:00 ET

Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 5:00 p.m. Eastern Time...

Jul 29, 2015, 08:00 ET

Arena Pharmaceuticals Initiates a Phase 2 Clinical Trial of APD334, its S1P1 Receptor Modulator for Autoimmune Diseases

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of patient screening in a Phase 2 proof-of-concept clinical trial of...

Jun 16, 2015, 16:30 ET

Arena Pharmaceuticals Announces the Departure of Chief Financial Officer

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Robert E. Hoffman, Senior Vice President, Finance and Chief Financial Officer, has...

Jun 04, 2015, 13:30 ET

Lorcaserin HCl Data to be Presented at American Diabetes Association's 75th Scientific Sessions

 Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the following poster regarding lorcaserin HCl will be...

May 26, 2015, 08:00 ET

Arena Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at...

May 14, 2015, 08:00 ET

Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin HCl Data at Upcoming Medical Meetings

 Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that lorcaserin HCl data will be presented at the following medical...

May 11, 2015, 16:07 ET

Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2015 Financial Results

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the first quarter ended March...

May 11, 2015, 16:01 ET

Arena Pharmaceuticals and Roivant Sciences Enter into Collaboration for Nelotanserin, a Novel Inverse Agonist of the 5-HT2A Receptor

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that its subsidiary, Arena Pharmaceuticals GmbH, and Roivant Sciences Ltd., have entered...

May 08, 2015, 08:00 ET

Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the...

May 07, 2015, 08:00 ET

Arena Pharmaceuticals to Host First Quarter 2015 Financial Results Conference Call and Webcast on Monday, May 11

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 5:00 p.m. Eastern Time...

Apr 29, 2015, 08:00 ET

Arena Pharmaceuticals Reports Favorable Results from Phase 1 Single-Ascending Dose Clinical Trial of APD371

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced favorable results from a Phase 1 single-ascending dose clinical trial of APD371, a...

Apr 10, 2015, 08:00 ET

Eisai and Arena Pharmaceuticals Complete Registrational Trials of an Extended Release Formulation of Lorcaserin

 Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the completion of two Phase 1 registrational clinical trials that...

Apr 09, 2015, 08:00 ET

Arena Pharmaceuticals to Present at the Annual Needham Healthcare Conference

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at...

Apr 07, 2015, 08:00 ET

Arena Pharmaceuticals Receives Additional Patent for BELVIQ® (lorcaserin HCl) from United States Patent and Trademark Office

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc., announced today that the US Patent and Trademark Office granted Arena US Patent No....

Mar 02, 2015, 16:01 ET

Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2014 Financial Results

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full...

Feb 23, 2015, 08:00 ET

Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2014 Financial Results Conference Call and Webcast on Monday, March 2

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00...

Feb 18, 2015, 08:00 ET

Arena Pharmaceuticals to Present at the 2015 RBC Capital Markets Healthcare Conference

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at...

Feb 04, 2015, 03:00 ET

Arena Pharmaceuticals GmbH annonce l'autorisation de commercialisation en Corée du Sud de BELVIQ® (hydrochlorure de lorcasérine) pour la gestion des déséquilibres de poids

-- L'autorisation déclenche un paiement d'étape de 3 millions de dollars US --  Arena Pharmaceuticals GmbH, une filiale à...

Feb 04, 2015, 03:00 ET

Arena Pharmaceuticals GmbH verkündet Zulassung für die Vermarktung von BELVIQ® (Lorcaserin HCl) als Behandlungsmittel für dauerhaftes Gewichtsmanagement in Südkorea

-- Zulassung löst Meilensteinzahlung in Höhe von 3 Millionen US-Dollar aus --  Arena Pharmaceuticals GmbH, eine...

Feb 03, 2015, 05:00 ET

Arena Pharmaceuticals Announces Marketing Approval in South Korea of BELVIQ® (lorcaserin HCl) for Weight Management

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Ildong Pharmaceutical Co., Ltd., has informed Arena that the Ministry of Food and...